english.prescrire.org > Spotlight > Archives : 2023 > Rimegepant (Vydura°) in migraine

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2023 : 1 | 30 | 60

Rimegepant (Vydura°) in migraine

 Marketing Authorisations   Rimegepant is another CGRP receptor antagonist, with a chemical structure completely different from that of the monoclonal antibodies initially available. It is the first CGRP inhibitor to be authorised in the European Union for oral administration, both for the treatment and prevention of migraine attacks.
Full article (4 pages) available for download by subscribers

EDITORS' OPINION
Placebomania

Comparing a new drug to a placebo is a justifiable choice if no standard treatment exists. Otherwise, it is a choice that is not in patients' interests...

Full text available for download by subscribers

©Prescrire 1 October 2023

Source: "Rimegepant (Vydura°) in migraine" Prescrire Int 2023; 32 (252): 229-232. Subscribers only.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


See also:

"Erenumab (Aimovig°)
for the prevention
of migraine attacks"
Prescrire Int 2019;
28 (207): 201-205.
Subscribers only

"Erenumab: hypertension"
Prescrire Int 2021;
30 (231): 266.
Subscribers only


Read more:

This month's contents

All the subjects in
Prescrire's spotlight